The 7 major facioscapulohumeral muscular dystrophy markets reached a value of USD 32.2 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 61.4 Million by 2035, exhibiting a growth rate (CAGR) of 6.12% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 32.2 Million |
Market Forecast in 2035
|
USD 61.4 Million |
Market Growth Rate (2025-2035)
|
6.12% |
The facioscapulohumeral muscular dystrophy market has been comprehensively analyzed in IMARC's new report titled "Facioscapulohumeral Muscular Dystrophy (FSHD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". FSHD is an inherited neuromuscular condition that is diagnosed by progressive weakening and atrophy of the muscles, mainly facial (facio), shoulder (scapulo), and arm (humeral) muscles. The condition tends to occur asymmetrically, either in adolescence or early adulthood, though its impact and rate of progression are different in each. Although FSHD is not fatal, it has a marked effect on mobility, daily life, and well-being. Symptoms are varied and include impairment of eye closure, winging of the scapulae, weakness in the upper limb, foot drop, and limb involvement in later stages. Additional symptoms include hearing loss and abnormalities in the retina. Diagnosis can be made clinically, with confirmation by electromyography (EMG), muscle biopsy, and genetic testing. The D4Z4 repeat contraction on 4q35 is a confirmed biomarker. Advances in genetic testing, biomarker research, and personalized medicine are enhancing early diagnosis and disease management, opening up opportunities for market growth.
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is mainly fueled by the increasing incidence of genetic neuromuscular diseases, as well as improvements in precision medicine and gene-targeted therapies. FSHD is due to genetic mutations resulting in the aberrant expression of the DUX4 protein, which causes progressive muscle degeneration. This has prompted widespread research into disease-modifying therapies, with a number of pipeline drugs targeting epigenetic modulation, gene silencing, and DUX4 inhibition. Firms are now investing in RNA-based therapies and CRISPR gene-editing technologies to establish targeted methods addressing the cause of FSHD. Moreover, physiotherapy, rehabilitation regimes, supportive equipment, and symptomatic treatments are becoming more prominent as adjunctive care to enhance patients' mobility and well-being. Increasing utilization of anti-inflammatory drugs and myostatin inhibitors to maintain muscle function is also broadening the therapeutic pipeline. Government grants, patient advocacy programs, and rising clinical trial enrollments are driving the growth of new therapies. With the advancement of biopharmaceutical innovation, the market is anticipated to see increased treatment availability, which will spur growth throughout the forecast period.
IMARC Group's new report provides an exhaustive analysis of the facioscapulohumeral muscular dystrophy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, Europe has the largest patient pool for facioscapulohumeral muscular dystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the facioscapulohumeral muscular dystrophy market in any manner.
Delpacibart braxlosiran (del-brax) is an experimental Antibody Oligonucleotide Conjugate (AOC) treatment developed by Avidity Biosciences to treat the root cause of facioscapulohumeral muscular dystrophy (FSHD). In the Phase 1/2 FORTITUDE™ clinical trial, del-brax showed more than 50% decrease in DUX4 regulated genes, functional improvement trends, and good safety and tolerability.
ARO-DUX4 is Arrowhead Pharmaceuticals' experimental RNA interference (RNAi) therapy that targets the DUX4 gene, associated with facioscapulohumeral muscular dystrophy (FSHD). Through selective knockdown of DUX4, ARO-DUX4 intends to stop the muscle degeneration and enhance the function of the muscles in patients suffering from FSHD. A Phase 1/2 clinical trial has been proposed to test its efficacy and safety.
RG 6237 (GYM329) is an experimental anti-latent myostatin antibody produced by Chugai Pharmaceutical and Roche. It is designed to block myostatin, a muscle growth regulator, with the purpose of increasing muscle strength and mass. In Phase II trials for facioscapulohumeral muscular dystrophy (FSHD), RG 6237 is given subcutaneously.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current facioscapulohumeral muscular dystrophy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Delpacibart braxlosiran | Avidity Biosciences |
ARO-DUX4 | Arrowhead Pharmaceuticals |
RG 6237 | Chugai Pharmaceutical/Roche |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Facioscapulohumeral Muscular Dystrophy (FSHD): Current Treatment Scenario, Marketed Drugs and Emerging Therapies